We previously showed that therapy experiment with two different immunocytokines, able to induce complete tumor rejections in BALB/c mice, resulted in an expansion of AH1-reactive CD8+ lymphocytes, which protected the host from subsequent challenges with diverse AH1-expressing tumors [21, 22]. This evidence concerns the gene CD8A and neoplasm.